Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$120.08 USD

120.08
3,823,779

+9.80 (8.89%)

Updated Aug 8, 2025 10:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $62.32 in the latest trading session, marking a +1.02% move from the prior day.

Zacks Equity Research

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PJP

Zacks Equity Research

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $62.63, moving +0.47% from the previous trading session.

Zacks Equity Research

The Zacks Analyst Blog Highlights Union Pacific, AT&T, Blackstone, Gilead Sciences and Waste Management

by Zacks Equity Research

Union Pacific, AT&T, Blackstone, Gilead Sciences and Waste Management are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Union Pacific, AT&T & Blackstone

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Union Pacific Corporation (UNP), AT&T Inc. (T) and Blackstone Inc. (BX).

Zacks Equity Research

Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.

Zacks Equity Research

Should Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for LVHD

Zacks Equity Research

Gilead Sciences (GILD) Stock Moves -1.67%: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $63.50 in the latest trading session, marking a -1.67% move from the prior day.

Zacks Equity Research

Merck (MRK) Resumes HIV Studies on Islatravir With Lower Dose

by Zacks Equity Research

Merck's (MRK) new phase III studies are set to evaluate a once-daily oral combination of doravirine and a lower dose of islatravir

Zacks Equity Research

Gilead (GILD) Drugs Get Positive CHMP Opinion for Label Expansion

by Zacks Equity Research

Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.

Zacks Equity Research

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

Zacks Equity Research

WHO Recommends Gilead's (GILD) Veklury for Severe COVID-19

by Zacks Equity Research

Gilead's (GILD) Veklury is now recommended by the WHO for use in both non-severe COVID-19 patients at the highest risk of hospitalization and those with severe COVID-19.

Zacks Equity Research

Gilead Sciences (GILD) Stock Moves -0.28%: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $65, marking a -0.28% move from the previous day.

Zacks Equity Research

Gilead (GILD) Up on Settling HIV Drug Suit With Generic Players

by Zacks Equity Research

Gilead (GILD) enters settlement agreements with a few generic manufacturers to resolve the litigation and patent challenges associated with HIV treatments, such as Descovy, Vemlidy and Odefsey.

Zacks Equity Research

Company News for Sep 13, 2022

by Zacks Equity Research

Companies in The News Are: AAPL, BMY, TWTR, GILD

Zacks Equity Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Zacks Equity Research

Should First Trust Large Cap Core AlphaDEX ETF (FEX) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FEX

Zacks Equity Research

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $65.28, marking a +0.28% move from the previous day.

Zacks Equity Research

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $65.10, moving +0.48% from the previous trading session.

Zacks Equity Research

Gilead (GILD) Breast Cancer Drug Trodelvy Improves Survival

by Zacks Equity Research

Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy.

Zacks Equity Research

Halozyme Therapeutics (HALO) Down 10.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Zacks Equity Research

Is First Trust Large Cap Core AlphaDEX ETF (FEX) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FEX

Zacks Equity Research

Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication

by Zacks Equity Research

The European Commission approves Gilead's (GILD) CAR T-cell therapy, Tecartus, for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Zacks Equity Research

Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & More

by Zacks Equity Research

Regulatory and acquisition updates from Gilead (GILD) and Forma (FMTX) are key highlights from the biotech sector during the past week.